Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition

Hypertension

Volumn 44, Issue 6, 2004, Pages 913-918

  Cruden, Nicholas L M ^a   Fox, Keith A A ^a   Ludlam, Christopher A ^a   Johnston, Neil R ^a   Newby, David E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Angiotensin converting enzyme; Bradykinin; Endothelium; Heart failure

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRADYKININ; BRADYKININ DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; NITROPRUSSIDE SODIUM; PLACEBO; PLASMINOGEN ACTIVATOR; THIORPHAN;

ADULT; AGED; ARTICLE; BLOOD FLOW; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; HEART FAILURE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASODILATATION;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL NATRIURETIC FACTOR; BRADYKININ; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NEPRILYSIN; NITROPRUSSIDE; PROTEASE INHIBITORS; RECEPTOR, BRADYKININ B1; THIORPHAN; TISSUE PLASMINOGEN ACTIVATOR; VASODILATION; VASODILATOR AGENTS;

EID: 9644268762     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000146483.78994.56     Document Type: Article

References (44)

1. Witherow FN, Dawson P, Ludlam CA, Fox KA, Newby DE. Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J Am Coll Cardiol. 2002;40:961-966.
2. 2 receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation. 2000;102:2190-2196.
3. 1 receptors for kinins. Pharmacol Rev. 1998;50:357-386.
4. 1-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation. 2002;105:627-632.
5. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
6. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292.
7. Witherow FN, Helmy A, Webb DJ, Fox KA, Newby DE. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation. 2001;104:2177-2181.
8. 9-bradykinin metabolic pathways and kinetics of activation of human plasma. Am J Physiol Heart Circ Physiol 2001;281:H275-H283.
9. Benjamin N, Cockcroft JR, Collier JG, Dollery CT, Ritter JM, Webb DJ. Local inhibition of converting enzyme and vascular responses to angiotiensin and bradykinin in the human forearm. J Physiol. 1989;412:543-555.
10. Kuga T, Mohri M, Egashira K, Hirakawa Y, Tagawa T, Shimokawa H, Takeshita A. Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme. J Am Coll Cardiol. 1997;30:108-112.
11. Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 1993;45:87-146.
12. Fielitz J, Dendorfer A, Pregla R, Ehler E, Zurbrugg HR, Bartunek J, Hetzer R, Regitz-Zagrosek V. Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure. Circulation. 2002;105:286-289.
13. Knecht M, Pagel I, Langenickel T, Philipp S, Scheuermann-Freestone M, Willnow T, Bruemmer D, Graf K, Dietz R, Willenbrock R. Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci. 2002;71:2701-2712.
14. Dumoulin MJ, Adam A, Blais C Jr, Lamontagne D. Metabolism of bradykinin by the rat coronary vascular bed. Cardiovasc Res. 1998;38:229-236.
15. Graf K, Grafe M, Bossaller C, Niehus J, Schulz KD, Auch-Schwelk W, Fleck E. Degradation of bradykinin by neutral endopeptidase (EC 3.4.24.11) in cultured human endothelial cells. Eur J Clin Chem Clin Biochem. 1993;31:267-272.
16. Krassoi I, Pataricza J, Papp JG. Thiorphan enhances bradykinin-induced vascular relaxation in hypoxic/hyperkalaemic porcine coronary artery. J Pharm Pharmacol. 2003;55:339-345.
17. Northridge DB, Jardine AG, Alabaster CT, Barclay PL, Connell JM, Dargie HJ, Duly SG, Findlay IN, Lever AF, Samuels GM. Effects of UK 69 578: a novel atriopeptidase inhibitor. Lancet. 1989;2:591-593.
18. Richards M, Espiner E, Frampton C, Ikram H, Yandle T, Sopwith M, Cussans N. Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. Hypertension. 1990;16:269-276.
19. Favrat B, Burnier M, Nussberger J, Lecomte JM, Brouard R, Waeber B, Brunner HR. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens. 1995;13:797-804.
20. Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnes GT. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992;10:607-613.
21. Northridge DB, Newby DE, Rooney E, Norrie J, Dargie HJ. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. Am Heart J. 1999;138:1149-1157.
22. Dumoulin MJ, Adam A, Rouleau JL, Lamontagne D. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed. J Cardiovasc Pharmacol. 2001;37:359-366.
23. Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad MM. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol. 1999;34:782-790.
24. Xu J, Carretero OA, Liu YH, Yang F, Shesely EG, Oja-Tebbe N, Yang XP. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure. J Card Fail. 2004;10:83-89.
25. Campese VM, Lasseter KC, Ferrario CM, Smith WB, Ruddy MC, Grim CE, Smith RD, Vargas R, Habashy MF, Vesterqvist O, Delaney CL, Liao WC. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension. 2001;38:1342-1348.
26. McClean DR, Ikram H, Garlick AH, Richards AM, Nicholls MG, Crozier IG. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol. 2000;36:479-486.
27. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920-926.
28. Newby DE, Wright RA, Ludlam CA, Fox KA, Boon NA, Webb DJ. An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost. 1997;78:1242-1248.
29. Holmquist B, Bunning P, Riordan JF. A continuous spectrophotometric assay for angiotensin converting enzyme. Anal Biochem. 1979;95:540-548.
30. Ferro CJ, Spratt JC, Haynes WG, Webb DJ. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation. 1998;97:2323-2330.
31. Barclay PL, Danilewicz JC, Samuels GM. Inhibitory potencies of UK-69 578 and thiorphan. Lancet. 1990;336:754-755.
32. van der Zander K, Houben AJ, Kroon AA, de Leeuw PW. Effects of brain natriuretic peptide on forearm vasculature: comparison with atrial natriuretic peptide. Cardiovasc Res. 1999;44:595-600.
33. Gobeil F, Pheng LH, Badini I, Nguyen-Le XK, Pizard A, Rizzi A, Blouin D, Regoli D. Receptors for kinins in the human isolated umbilical vein. Br J Pharmacol. 1996;118:289-294.
34. 1 receptors for kinins. J Pharmacol Exp Ther. 1991;259:997-1003.
35. 1 receptor agonist in a non-human primate model: haemodynamic and pro-inflammatory effects. Br J Pharmacol. 2001;132:327-335.
36. Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation. 2003;107:579-585.
37. Azizi M, Lamarre-Cliche M, Labatide-Alanore A, Bissery A, Guyene TT, Menard J. Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake. J Am Soc Nephrol. 2002;13:2454-2463.
38. Regamey F, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal hemodynamic and natriuretic effects of concomitant angiotensin-converting enzyme and neutral endopeptidase inhibition in men. Hypertension. 2002;40:266-272.
39. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693-1697.
40. Armstrong PW, Lorell BH, Nissen S, Borer J. Omapatrilat. Circulation. 2002;106:e9011e-e9012.
41. Cockcroft JR, Allen MJ, Benjamin N, Webb DJ. The effect of local angiotensin converting enzyme inhibition on the action of atrial natriuretic peptide in the human forearm. J Hum Hypertens. 1989;3:49-52.
42. Hirooka Y, Takeshita A, Imaizumi T, Suzuki S, Yoshida M, Ando S, Nakamura M. Attenuated forearm vasodilataive response to intra-arterial atrial natriuretic peptide in patients with heart failure. Circulation. 1990;82:147-153.
43. Pawlowska Z, Jerczynska H, Szemraj J, Baranska P, Swiatkowska M, Cierniewski CS. Natriuretic peptides reduce plasminogen activator inhibitor-1 expression in human endothelial cells. Cell Mol Biol Lett. 2002;7:1153-1157.
44. Jorde UP, Ennezat PV, Lisker J, Suryadevara V, Infeld J, Cukon S, Hammer A, Sonnenblick EH, Le Jemtel TH. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation. 2000;101:844-846.